Michael Douglas Taylor Sells 22,500 Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 22,500 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $40.77, for a total transaction of $917,325.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of DCPH stock traded up $15.95 on Tuesday, hitting $35.90. The stock had a trading volume of 10,854,326 shares, compared to its average volume of 291,452. Deciphera Pharmaceuticals Inc has a twelve month low of $18.55 and a twelve month high of $42.99. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -12.73 and a beta of 2.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The company has a fifty day simple moving average of $22.57.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.56. The firm had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. Research analysts expect that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current year.



Several analysts have commented on the stock. Guggenheim upped their target price on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Jaffray Companies boosted their price target on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. BidaskClub raised shares of Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 2nd. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price target for the company in a report on Monday, August 5th. Finally, ValuEngine raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $43.67.

Several hedge funds have recently made changes to their positions in DCPH. Norges Bank acquired a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at $6,974,000. Dimensional Fund Advisors LP acquired a new position in Deciphera Pharmaceuticals in the 4th quarter worth $4,337,000. Alps Advisors Inc. acquired a new position in Deciphera Pharmaceuticals in the 2nd quarter worth $1,802,000. Marshall Wace North America L.P. boosted its stake in Deciphera Pharmaceuticals by 4,025.4% in the 1st quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after purchasing an additional 56,315 shares during the period. Finally, CIBC Asset Management Inc boosted its stake in Deciphera Pharmaceuticals by 120.9% in the 2nd quarter. CIBC Asset Management Inc now owns 91,142 shares of the company’s stock worth $2,055,000 after purchasing an additional 49,884 shares during the period. 59.10% of the stock is owned by institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.